Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy (ImmunoPAX)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02332642
Recruitment Status :
First Posted : January 7, 2015
Last Update Posted : March 7, 2017
Information provided by (Responsible Party):
Dr. Christoffer Gebhardt, Universitätsmedizin Mannheim
This pilot clinical trial aims at evaluating immuno-modulating effects of palliative treatment with specifically dosed standard chemotherapeutics in patients with metastatic melanoma (AJCC stage IV) by assessing myeloid-derived suppressor cells' (MDSCs) count and activity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Metastatic melanoma patients (AJCC stage IV)
histologically defined metastatic melanoma patients (AJCC stage IV)
aged 18 to 80 years
at least one prior systemic anti-melanoma therapy; if BRAFV600 positive, at least one prior BRAFi therapy
any contra-indications for (specific) systemic chemotherapy